The Magazine for Sleep Professionals
Thursday, July 23, 2026
Aesyra, a medical device company pioneering oral appliance technologies to improve sleep, today announced it has raised $3 million in seed financing. The round was led by Supermoon Capital (USA), the world’s first fund focused on sleeptech, and deep tech investor Creadd Ventures (Switzerland) with participation from existing investor Zürcher […]
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (“CNS”) disorders, announced that NLS has entered into an exclusive worldwide option agreement with Aexon Labs, Inc., a privately held U.S. company (“Aexon Labs”), […]
Vivos Therapeutics, Inc. announced it has been granted 510(k) clearance from the U.S. Food and Drug Administration (FDA) for treating severe obstructive sleep apnea (OSA) in adults using the Vivos’ removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances. Vivos’ CARE appliances include the flagship DNA oral appliance, the mRNA […]
Jazz Pharmaceuticals plc announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil. The oral presentations include findings from the real-world TENOR study, […]
Harmony Biosciences Holdings, Inc. announced the presentation of new secondary endpoint data, including improvements in behavioral disturbances, from its Phase 2 signal-detection study evaluating pitolisant for the treatment of excessive daytime sleepiness (EDS) in Prader-Willi syndrome (PWS) at the 2023 Foundation for Prader-Willi Research (FPWR) Symposium and Family Conference. The […]
ProSomnus, Inc. has announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC. ProSomnus’s Executive Chair, Chief Executive Officer, and Chief Financial Officer are also participating in the financing. A description of the terms of the offering can […]
Jazz Pharmaceuticals plc announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023. One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and […]
Takeda announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy type 1 (NT1) was published in The New England Journal of Medicine. These data represent the first-ever clinical data to be published of an oral orexin agonist in NT1. The […]
ProSomnus, Inc. announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy (OAT) and hypoglossal nerve stimulation (HGNS) in treating patients with severe OSA. The clinical trial plans follow updated results from the First Line Obstructive Sleep Apnea Treatment Study (FLOSAT), a prospective, independent, head-to-head, crossover […]
SomnoMed North America announces Nexus Dental Systems (Nexus) as their preferred partner to offer sleep dentistry training and medical billing in the DOD, VA and commercial market segments. “This partnership significantly enhances the objectives of SomnoMed’s Medical Initiative by further enabling and expanding collaborative patient treatment pathways between medical prescribers, […]
